

Mario Santinami

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1646579/publications.pdf>

Version: 2024-02-01

163
papers

13,927
citations

36303

51
h-index

20961

115
g-index

170
all docs

170
docs citations

170
times ranked

15444
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles. <i>Journal of Investigative Dermatology</i> , 2022, 142, 3030-3040.e5. | 0.7 | 6 |
| 2 | The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (Nâ€™=â€™2,086). <i>BMC Cancer</i> , 2022, 22, . | 2.6 | 5 |
| 3 | Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021, 124, 574-580. | 6.4 | 27 |
| 4 | Surgical treatment of melanoma metastases to the small bowel: A single cancer referral center real-life experience. <i>European Journal of Surgical Oncology</i> , 2021, 47, 409-415. | 1.0 | 3 |
| 5 | The role of sentinel lymph node status performed in melanoma patients with local recurrence or in transit metastasis. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1152-1156. | 1.0 | 0 |
| 6 | Survival in Patients With Sentinel Nodeâ€™Positive Melanoma With Extranodal Extension. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1165-1173. | 4.9 | 3 |
| 7 | miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators. <i>Cell Communication and Signaling</i> , 2020, 18, 156. | 6.5 | 18 |
| 8 | Clinical applications of receptor-binding radiopharmaceutical 99mTc-Tilmanocept: sentinel node biopsy and beyond. <i>Clinical and Translational Imaging</i> , 2020, 8, 413-418. | 2.1 | 5 |
| 9 | Reply to E. Hindiâ€™. <i>Journal of Clinical Oncology</i> , 2020, 38, 3238-3240. | 1.6 | 3 |
| 10 | Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI). <i>European Journal of Cancer</i> , 2020, 137, 30-39. | 2.8 | 4 |
| 11 | Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020, 383, 1139-1148. | 27.0 | 256 |
| 12 | 1100P Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanoma. <i>Annals of Oncology</i> , 2020, 31, S743-S744. | 1.2 | 0 |
| 13 | Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram. <i>Journal of Clinical Oncology</i> , 2020, 38, 1591-1601. | 1.6 | 50 |
| 14 | Systemic Therapy for Melanoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 3947-3970. | 1.6 | 190 |
| 15 | Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 358-372. | 10.7 | 94 |
| 16 | Analysis of Sentinel Node Biopsy and Clinicopathologic Features as Prognostic Factors in Patients With Atypical Melanocytic Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1327-1336. | 4.9 | 3 |
| 17 | An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells. <i>Oncogene</i> , 2019, 38, 4384-4396. | 5.9 | 36 |
| 18 | Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 701-710. | 10.7 | 50 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-------|-----------|
| 19 | Reply to E. Hindi ¹ and K.R. Hess. Journal of Clinical Oncology, 2019, 37, 1356-1358. | 1.6 | 1 |
| 20 | Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO).. Journal of Clinical Oncology, 2019, 37, 9582-9582. | 1.6 | 1 |
| 21 | Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600 ⁺ Mutant Stage III Melanoma. Journal of Clinical Oncology, 2018, 36, 3441-3449. | 1.6 | 226 |
| 22 | Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. Annals of Oncology, 2018, 29, viii445. | 1.2 | 2 |
| 23 | MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2018, 19, 916-929. | 10.7 | 131 |
| 24 | Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial.. Journal of Clinical Oncology, 2018, 36, 9574-9574. | 1.6 | 1 |
| 25 | Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III <i>BRAF</i> -mutant melanoma.. Journal of Clinical Oncology, 2018, 36, 9590-9590. | 1.6 | 9 |
| 26 | Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected <i>BRAF</i> -mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification.. Journal of Clinical Oncology, 2018, 36, 9591-9591. | 1.6 | 8 |
| 27 | The inflammation markers in serum of tumor-bearing rats after plasmonic photothermal therapy. , 2018, , . | | 0 |
| 28 | Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases. Annals of Surgical Oncology, 2017, 24, 3991-4000. | 1.5 | 102 |
| 29 | Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca-A Cancer Journal for Clinicians, 2017, 67, 472-492. | 329.8 | 1,662 |
| 30 | Adjuvant Dabrafenib plus Trametinib in Stage III <i>BRAF</i> -Mutated Melanoma. New England Journal of Medicine, 2017, 377, 1813-1823. | 27.0 | 1,192 |
| 31 | Sex-specific effect of RNASEL rs486907 and miR-146a rs2910164 polymorphisms TM interaction as a susceptibility factor for melanoma skin cancer. Melanoma Research, 2017, 27, 309-314. | 1.2 | 13 |
| 32 | Prognostic factors in Merkel cell carcinoma patients undergoing sentinel node biopsy. European Journal of Surgical Oncology, 2017, 43, 1536-1541. | 1.0 | 13 |
| 33 | microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response. Genes, 2016, 7, 124. | 2.4 | 8 |
| 34 | Immunomodulatory Factors Control the Fate of Melanoma Tumor Initiating Cells. Stem Cells, 2016, 34, 2449-2460. | 3.2 | 21 |
| 35 | NFATc2 is an intrinsic regulator of melanoma dedifferentiation. Oncogene, 2016, 35, 2862-2872. | 5.9 | 43 |
| 36 | Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget, 2016, 7, 4428-4441. | 1.8 | 84 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | 3321 The role of sentinel lymph node biopsy in Merkel Cell Carcinoma: Analysis of 64 patients from a single institution. <i>European Journal of Cancer</i> , 2015, 51, S671. | 2.8 | 0 |
| 38 | Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 999-1009. | 4.2 | 138 |
| 39 | Lymph-Node Ratio in Patients with Cutaneous Melanoma: A Multi-Institution Prognostic Study. <i>Annals of Surgical Oncology</i> , 2015, 22, 2127-2134. | 1.5 | 18 |
| 40 | Factors predictive of pelvic lymph node involvement and outcomes in melanoma patients with metastatic sentinel lymph node of the groin: A multicentre study. <i>European Journal of Surgical Oncology</i> , 2015, 41, 823-829. | 1.0 | 11 |
| 41 | Differences in Clinicopathological Features and Distribution of Risk Factors in Italian Melanoma Patients. <i>Dermatology</i> , 2015, 230, 256-262. | 2.1 | 6 |
| 42 | Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. <i>Annals of Oncology</i> , 2015, 26, 798-803. | 1.2 | 118 |
| 43 | “Cancer Bio-Immunotherapy in Siena” Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 131-135. | 4.2 | 0 |
| 44 | ITOC2 “038. Role of exosomes in immune suppression. <i>European Journal of Cancer</i> , 2015, 51, S13. | 2.8 | 3 |
| 45 | Electrochemotherapy: a good idea in recurrent basal cell carcinoma treatment. <i>Melanoma Management</i> , 2015, 2, 27-31. | 0.5 | 3 |
| 46 | Armed antibodies for cancer treatment: a promising tool in a changing era. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 113-121. | 4.2 | 28 |
| 47 | The number of excised lymph nodes is associated with survival of melanoma patients with lymph node metastasis. <i>Annals of Oncology</i> , 2014, 25, 240-246. | 1.2 | 34 |
| 48 | Enrichment of CD56dimKIR+CD57+ highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. <i>Nature Communications</i> , 2014, 5, 5639. | 12.8 | 109 |
| 49 | Association of promoter polymorphism ~ 765 G²C in the PTGS² gene with malignant melanoma in Italian patients and its correlation to gene expression in dermal fibroblasts. <i>Experimental Dermatology</i> , 2014, 23, 766-768. | 2.9 | 4 |
| 50 | Number of Excised Lymph Nodes as a Quality Assurance Measure for Lymphadenectomy in Melanoma. <i>JAMA Surgery</i> , 2014, 149, 700. | 4.3 | 42 |
| 51 | Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression. <i>Cancer Research</i> , 2014, 74, 130-140. | 0.9 | 27 |
| 52 | Accuracy and prognostic value of sentinel lymph node biopsy in head and neck melanomas. <i>Journal of Surgical Research</i> , 2014, 187, 518-524. | 1.6 | 28 |
| 53 | Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1893-1902. | 0.7 | 74 |
| 54 | Prediction of Survival in Patients With Thin Melanoma: Results From a Multi-Institution Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 2479-2485. | 1.6 | 103 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Nonsentinel Lymph Node Status in Patients With Cutaneous Melanoma: Results From a Multi-Institution Prognostic Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 935-941. | 1.6 | 49 |
| 56 | Enrichment of KIR+CD57+ highly cytotoxic NK cells in sentinel lymph nodes of melanoma patients. <i>Journal of Translational Medicine</i> , 2014, 12, P10. | 4.4 | 0 |
| 57 | Cutaneous Melanoma in Children and Adolescents: The Italian Rare Tumors in Pediatric Age Project Experience. <i>Journal of Pediatrics</i> , 2014, 164, 376-382.e2. | 1.8 | 47 |
| 58 | A phase II study of intratumoral application of L191L2/L19TNF in melanoma patients in clinical stage III or stage IV M1a with presence of injectable cutaneous and/or subcutaneous lesions.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS9103-TPS9103. | 1.6 | 4 |
| 59 | Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. <i>Journal of Surgical Oncology</i> , 2013, 107, 173-179. | 1.7 | 72 |
| 60 | Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study). <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1223-1233. | 4.2 | 5 |
| 61 | Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 897-908. | 4.2 | 31 |
| 62 | The use of polytetrafluoroethylene to facilitate the vascular access in recurrent melanoma to limbs. <i>International Journal of Surgery Case Reports</i> , 2013, 4, 40-43. | 0.6 | 1 |
| 63 | A variant in FTO shows association with melanoma risk not due to BMI. <i>Nature Genetics</i> , 2013, 45, 428-432. | 21.4 | 111 |
| 64 | Biological insights into BRAF ^{V600} mutations in melanoma patient. <i>Oncolmmunology</i> , 2013, 2, e25594. | 4.6 | 6 |
| 65 | Clinical and immunologic responses in melanoma patients vaccinated with MAGE-3 genetically modified lymphocytes. <i>International Journal of Cancer</i> , 2013, 132, 2557-2566. | 5.1 | 20 |
| 66 | CDKN2A and MC1R variants influence dermoscopic and confocal features of benign melanocytic lesions in multiple melanoma patients. <i>Experimental Dermatology</i> , 2013, 22, 411-416. | 2.9 | 26 |
| 67 | Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3831-3837. | 1.6 | 88 |
| 68 | Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 3810-3818. | 1.6 | 254 |
| 69 | Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes. <i>Cancer Research</i> , 2012, 72, 2746-2756. | 0.9 | 470 |
| 70 | Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I Modified Peptides. <i>Clinical Cancer Research</i> , 2012, 18, 6485-6496. | 7.0 | 61 |
| 71 | Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. <i>European Journal of Cancer</i> , 2012, 48, 218-225. | 2.8 | 182 |
| 72 | Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 879-886. | 10.7 | 273 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Small Nodular Melanoma: The Beginning of a Life-Threatening Lesion. A Clinical Study on 11 Cases. <i>Tumori</i> , 2011, 97, 35-38. | 1.1 | 9 |
| 74 | EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon- β (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up.. <i>Journal of Clinical Oncology</i> , 2011, 29, 8506b-8506b. | 1.6 | 13 |
| 75 | A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial.. <i>Journal of Clinical Oncology</i> , 2011, 29, TPS230-TPS230. | 1.6 | 5 |
| 76 | Pure Desmoplastic Melanoma. <i>Annals of Surgery</i> , 2010, 252, 1052-1057. | 4.2 | 49 |
| 77 | pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. <i>International Journal of Cancer</i> , 2010, 127, 207-219. | 5.1 | 237 |
| 78 | Phase III Trial Comparing Adjuvant Treatment With Pegylated Interferon Alfa-2b Versus Observation: Prognostic Significance of Autoantibodies in EORTC 18991. <i>Journal of Clinical Oncology</i> , 2010, 28, 2460-2466. | 1.6 | 69 |
| 79 | Tumor-Reactive CD8+ Early Effector T Cells Identified at Tumor Site in Primary and Metastatic Melanoma. <i>Cancer Research</i> , 2010, 70, 8378-8387. | 0.9 | 52 |
| 80 | Heterogeneous Phenotype of Human Melanoma Cells with In Vitro and In Vivo Features of Tumor-Initiating Cells. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1877-1886. | 0.7 | 77 |
| 81 | Response to Griewank and Bastian. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2331-2332. | 0.7 | 0 |
| 82 | High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients. <i>PLoS ONE</i> , 2009, 4, e5219. | 2.5 | 806 |
| 83 | Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 2916-2923. | 1.6 | 119 |
| 84 | Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage. <i>Clinical Cancer Research</i> , 2009, 15, 4085-4094. | 7.0 | 29 |
| 85 | Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1159-1167. | 4.2 | 21 |
| 86 | Cutaneous Melanoma in Childhood and Adolescence Shows Frequent Loss of INK4A and Gain of KIT. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1759-1768. | 0.7 | 54 |
| 87 | New common variants affecting susceptibility to basal cell carcinoma. <i>Nature Genetics</i> , 2009, 41, 909-914. | 21.4 | 303 |
| 88 | Single-Institution Series of Early-Stage Merkel Cell Carcinoma: Long-Term Outcomes in 95 Patients Managed with Surgery Alone. <i>Annals of Surgical Oncology</i> , 2009, 16, 2985-2993. | 1.5 | 50 |
| 89 | Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). <i>European Journal of Cancer</i> , 2009, 45, 3189-3197. | 2.8 | 48 |
| 90 | Radical dissection after positive groin sentinel biopsy in melanoma patients: rate of further positive nodes. <i>Melanoma Research</i> , 2009, 19, 112-118. | 1.2 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | Banked venous homograft replacement of the inferior vena cava for primary leiomyosarcoma. <i>European Journal of Surgical Oncology</i> , 2008, 34, 720-724. | 1.0 | 18 |
| 92 | Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. <i>Lancet</i> , The, 2008, 372, 117-126. | 13.7 | 620 |
| 93 | Metamorphosis of melanoma. Trends in size and thickness of cutaneous melanoma over one decade at the Istituto Nazionale Tumori, Milan. <i>Tumori</i> , 2008, 94, 11-13. | 1.1 | 22 |
| 94 | Adjuvant multi-peptide vaccination in high-risk early melanoma patients. <i>Journal of Clinical Oncology</i> , 2008, 26, 3014-3014. | 1.6 | 3 |
| 95 | Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. <i>Annals of Oncology</i> , 2007, 18, 226-232. | 1.2 | 252 |
| 96 | Melanoma immunology: past, present and future. <i>Current Opinion in Oncology</i> , 2007, 19, 121-127. | 2.4 | 57 |
| 97 | INV 4 Impaired response to ??c cytokines in T cells from melanoma patients. <i>Melanoma Research</i> , 2007, 17, A2. | 1.2 | 0 |
| 98 | Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. <i>European Journal of Cancer</i> , 2007, 43, 935-946. | 2.8 | 523 |
| 99 | Multispectral imaging and artificial neural network: mimicking the management decision of the clinician facing pigmented skin lesions. <i>Physics in Medicine and Biology</i> , 2007, 52, 2599-2613. | 3.0 | 58 |
| 100 | Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. <i>International Journal of Cancer</i> , 2007, 120, 2439-2444. | 5.1 | 76 |
| 101 | Advanced Extremity Soft Tissue Sarcoma: Prognostic Effect of Isolated Limb Perfusion in a Series of 88 Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2007, 14, 553-559. | 1.5 | 61 |
| 102 | EORTC 18991: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 8504-8504. | 1.6 | 18 |
| 103 | CD133 POSTIVE CELLULAR POPULATION IN HUMAN MELANOMA. <i>FASEB Journal</i> , 2007, 21, A32. | 0.5 | 0 |
| 104 | Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients and modulation by GM-CSF-based anti-tumor vaccine. <i>Journal of Clinical Oncology</i> , 2007, 25, 21082-21082. | 1.6 | 1 |
| 105 | Micro-melanoma detection: a clinical study on 206 consecutive cases of pigmented skin lesions with a diameter $\leq 3\text{ mm}$. <i>British Journal of Dermatology</i> , 2006, 155, 570-573. | 1.5 | 66 |
| 106 | A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon- γ in metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 958-968. | 4.2 | 134 |
| 107 | Sentinel and Nonsentinel Node Status in Stage IB and II Melanoma Patients: Two-Step Prognostic Indicators of Survival. <i>Journal of Clinical Oncology</i> , 2006, 24, 4464-4471. | 1.6 | 132 |
| 108 | Vaccination: role in metastatic melanoma. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1305-1318. | 2.4 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Immunization of Stage IV Melanoma Patients with Melan-A/MART-1 and gp100 Peptides plus IFN- γ Results in the Activation of Specific CD8+ T Cells and Monocyte/Dendritic Cell Precursors. <i>Cancer Research</i> , 2006, 66, 4943-4951. | 0.9 | 108 |
| 110 | Hyperthermic isolation limb perfusion with TNF α in the treatment of in-transit melanoma metastasis. <i>In Vivo</i> , 2006, 20, 739-42. | 1.3 | 6 |
| 111 | Evaluation of Myeloid Suppressive Cells in Peripheral Blood of Melanoma Patients and Their Modulation by A Heat-shock Protein (HSP)-96 and GM-CSF-based Vaccine. <i>Journal of Immunotherapy</i> , 2005, 28, 659. | 2.4 | 0 |
| 112 | Does Melanoma Behave Differently in Younger Children Than in Adults? A Retrospective Study of 33 Cases of Childhood Melanoma From a Single Institution. <i>Pediatrics</i> , 2005, 115, 649-654. | 2.1 | 215 |
| 113 | Automated segmentation of pigmented skin lesions in multispectral imaging. <i>Physics in Medicine and Biology</i> , 2005, 50, N345-N357. | 3.0 | 17 |
| 114 | Constitutive Expression and Costimulatory Function of LIGHT/TNFSF14 on Human Melanoma Cells and Melanoma-Derived Microvesicles. <i>Cancer Research</i> , 2005, 65, 3428-3436. | 0.9 | 53 |
| 115 | Narrower Surgical Margins Might be Sufficient in Invasive Horizontal Growth Phase Melanoma. <i>Tumori</i> , 2004, 90, 464-466. | 1.1 | 0 |
| 116 | Heat Shock Proteins and Their Use as Anticancer Vaccines. <i>Clinical Cancer Research</i> , 2004, 10, 8142-8146. | 7.0 | 62 |
| 117 | Atypical pleomorphic epithelioid angiomylipoma localized to the pelvis: a case report and review of the literature. <i>Histopathology</i> , 2004, 44, 292-295. | 2.9 | 17 |
| 118 | Retroperitoneal soft tissue sarcomas. <i>Cancer</i> , 2004, 100, 2448-2455. | 4.1 | 167 |
| 119 | Immunotherapy of melanoma. <i>Seminars in Cancer Biology</i> , 2003, 13, 391-400. | 9.6 | 48 |
| 120 | World Health Organization experience in the treatment of melanoma. <i>Surgical Clinics of North America</i> , 2003, 83, 405-416. | 1.5 | 17 |
| 121 | Chordoma: Natural History and Results in 28 Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2003, 10, 291-296. | 1.5 | 204 |
| 122 | Quality of Surgery and Outcome in Extra-Abdominal Aggressive Fibromatosis: A Series of Patients Surgically Treated at a Single Institution. <i>Journal of Clinical Oncology</i> , 2003, 21, 1390-1397. | 1.6 | 326 |
| 123 | Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma. <i>Melanoma Research</i> , 2003, 13, 51-58. | 1.2 | 21 |
| 124 | E-cadherin Expression on Fine Needle Aspiration Biopsies of Breast Invasive Ductal Carcinomas and Its Relationship to Clinicopathologic Factors. <i>Acta Cytologica</i> , 2003, 47, 363-367. | 1.3 | 8 |
| 125 | Surgical management of primary melanoma. , 2003, , 247-254. | | 0 |
| 126 | Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. <i>Cancer Research</i> , 2003, 63, 2535-45. | 0.9 | 142 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 127 | Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma. American Journal of Surgery, 2002, 183, 28-36. | 1.8 | 25 |
| 128 | DNA fragmentation and cell proliferation correlated with tumor grade in patients with hepatocellular carcinoma. Cancer, 2002, 96, 301-305. | 4.1 | 9 |
| 129 | Clinical and dermatoscopic diagnosis of small pigmented skin lesions. European Journal of Dermatology, 2002, 12, 573-6. | 0.6 | 12 |
| 130 | Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet, The, 2001, 358, 866-869. | 13.7 | 248 |
| 131 | Impact of Clinical Trials on the Treatment of Melanoma. Surgical Oncology Clinics of North America, 2001, 10, 935-947. | 1.5 | 13 |
| 132 | Isolated Limb Perfusion. Surgical Oncology Clinics of North America, 2001, 10, 821-832. | 1.5 | 38 |
| 133 | Sentinel Lymph Node Biopsy in Cutaneous Melanoma: The WHO Melanoma Program Experience. Annals of Surgical Oncology, 2000, 7, 469-474. | 1.5 | 318 |
| 134 | Sentinel Node Biopsy and Selective Lymph Node Dissection in Cutaneous Melanoma Patients. , 2000, , 235-242. | | 9 |
| 135 | Hyperthermic Antitlastic Perfusion with Alpha Tumor Necrosis Factor and Doxorubicin for the Treatment of Soft Tissue Limb Sarcoma in Candidates for Amputation. Journal of Immunotherapy, 1999, 22, 407-414. | 2.4 | 24 |
| 136 | Dissection of regional lymph nodes in cutaneous melanoma. Lancet, The, 1998, 351, 1885. | 13.7 | 0 |
| 137 | Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. Lancet, The, 1998, 351, 793-796. | 13.7 | 625 |
| 138 | Treatment of Recurrent Sarcoma of the Extremities by Isolated Limb Perfusion Using Tumor Necrosis Factor Alpha and Melphalan. Tumori, 1996, 82, 579-584. | 1.1 | 25 |
| 139 | Isolated Pelvic Perfusion for the Treatment of Unresectable Primary or Recurrent Rectal Cancer. Tumori, 1996, 82, 459-462. | 1.1 | 8 |
| 140 | Intraperitoneal hyperthermic perfusion (IPHP). Oncology Reports, 1996, 3, 1103-6. | 2.6 | 5 |
| 141 | Current results of pelvic perfusion for non-resectable relapsing of pelvic cancer. Oncology Reports, 1996, 3, 1097-1102. | 2.6 | 0 |
| 142 | Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma. Annals of Surgical Oncology, 1995, 2, 61-70. | 1.5 | 14 |
| 143 | Cardiac and Pulmonary Effects of Alpha Tumor Necrosis Factor Administered by Isolation Perfusion. Tumori, 1995, 81, 197-200. | 1.1 | 2 |
| 144 | Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. Cancer, 1994, 73, 483-492. | 4.1 | 75 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Hyperthermic antitlastic perfusion in the treatment of stage IIIA-IIIAB melanoma patients. Comparison of two experiences. <i>Melanoma Research</i> , 1994, 4, 269. | 1.2 | 3 |
| 146 | Excision of primary melanoma. <i>Melanoma Research</i> , 1993, 3, 13. | 1.2 | 4 |
| 147 | The role of tamoxifen (T) in association with chemotherapy in metastatic melanoma (MM). <i>Melanoma Research</i> , 1993, 3, 53. | 1.2 | 0 |
| 148 | Adoptive Immunotherapy of Melanoma with Interleukin-2 and Lymphocytes. , 1993, , 243-252. | | 0 |
| 149 | Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study. <i>Melanoma Research</i> , 1992, 2, 263-272. | 1.2 | 10 |
| 150 | Elective lymph node dissection for melanoma: Two perspectives. <i>World Journal of Surgery</i> , 1992, 16, 203-213. | 1.6 | 40 |
| 151 | Antitumor activity of hyperthermia alone or in combination with cisplatin and melphalan in primary cultures of human malignant melanoma. <i>International Journal of Cell Cloning</i> , 1989, 7, 385-394. | 1.6 | 17 |
| 152 | Management of nodal metastases from head and neck melanoma. <i>Journal of Surgical Oncology</i> , 1989, 42, 47-53. | 1.7 | 7 |
| 153 | Seven years experience with hyperthermic perfusions in extracorporeal circulation for melanoma of the extremities. <i>Journal of Surgical Oncology</i> , 1989, 42, 201-208. | 1.7 | 47 |
| 154 | Clinical status of diagnosis and therapy of malignant melanoma. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1989, 16, 621-624. | 0.3 | 1 |
| 155 | Isolation perfusion of the lower limb with platinum. <i>World Journal of Surgery</i> , 1988, 12, 307-309. | 1.6 | 10 |
| 156 | HLA Antigens in Familial and Sporadic Cutaneous Melanoma. <i>Tumori</i> , 1988, 74, 657-664. | 1.1 | 2 |
| 157 | Intra-arterial infusion and perfusion chemotherapy for soft tissue sarcomas of the extremities. <i>Cancer Treatment and Research</i> , 1986, , 103-129. | 0.5 | 5 |
| 158 | Limb-Salvage Procedure in Two Patients with Spindle Cell Carcinoma of the Lower Extremities using Isolation Perfusion. <i>Tumori</i> , 1985, 71, 271-275. | 1.1 | 4 |
| 159 | Hyperthermic Antitlastic Perfusion in the Treatment of Cancer of the Extremities. <i>Tumori</i> , 1985, 71, 355-359. | 1.1 | 25 |
| 160 | Prognosis of skin melanoma with regional node metastases (stage II). <i>Journal of Surgical Oncology</i> , 1984, 25, 240-247. | 1.7 | 83 |
| 161 | Regional Perfusion at High Temperature in Treatment of Stage IIIA-IIIAB Melanoma Patients. <i>Tumori</i> , 1983, 69, 585-588. | 1.1 | 20 |
| 162 | The advent of minimally invasive lymphadenectomy in melanoma. <i>Annals of Laparoscopic and Endoscopic Surgery</i> , 0, 2, 122-122. | 0.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|----|-----------|
| 163 | Cutaneous Melanoma - Surgical Treatment. , 0, , . | | 0 |